vs

Side-by-side financial comparison of Organogenesis Holdings Inc. (ORGO) and 1ST SOURCE CORP (SRCE). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $113.1M, roughly 2.0× 1ST SOURCE CORP). 1ST SOURCE CORP runs the higher net margin — 35.3% vs 19.4%, a 16.0% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 8.7%). 1ST SOURCE CORP produced more free cash flow last quarter ($58.1M vs $34.8M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 7.8%).

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

1st Source Corporation is a financial services company headquartered in South Bend, Indiana. It operates 1st Source Bank, a bank with 81 branches in Indiana and Michigan. The bank's Specialty Finance Group provides financing for aircraft, trucks, and construction equipment. 1st Source Insurance provides insurance products and services.

ORGO vs SRCE — Head-to-Head

Bigger by revenue
ORGO
ORGO
2.0× larger
ORGO
$225.6M
$113.1M
SRCE
Growing faster (revenue YoY)
ORGO
ORGO
+69.4% gap
ORGO
78.1%
8.7%
SRCE
Higher net margin
SRCE
SRCE
16.0% more per $
SRCE
35.3%
19.4%
ORGO
More free cash flow
SRCE
SRCE
$23.3M more FCF
SRCE
$58.1M
$34.8M
ORGO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
7.8%
SRCE

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ORGO
ORGO
SRCE
SRCE
Revenue
$225.6M
$113.1M
Net Profit
$43.7M
$40.0M
Gross Margin
Operating Margin
28.1%
45.4%
Net Margin
19.4%
35.3%
Revenue YoY
78.1%
8.7%
Net Profit YoY
469.5%
6.5%
EPS (diluted)
$0.31
$1.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORGO
ORGO
SRCE
SRCE
Q1 26
$113.1M
Q4 25
$225.6M
$110.8M
Q3 25
$150.9M
$110.7M
Q2 25
$101.0M
$108.2M
Q1 25
$86.7M
$104.0M
Q4 24
$126.7M
$97.8M
Q3 24
$115.2M
$97.9M
Q2 24
$130.2M
$97.3M
Net Profit
ORGO
ORGO
SRCE
SRCE
Q1 26
$40.0M
Q4 25
$43.7M
$41.1M
Q3 25
$21.6M
$42.3M
Q2 25
$-9.4M
$37.3M
Q1 25
$-18.8M
$37.5M
Q4 24
$7.7M
$31.4M
Q3 24
$12.3M
$34.9M
Q2 24
$-17.0M
$36.8M
Gross Margin
ORGO
ORGO
SRCE
SRCE
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
ORGO
ORGO
SRCE
SRCE
Q1 26
45.4%
Q4 25
28.1%
Q3 25
13.7%
49.7%
Q2 25
-12.5%
44.5%
Q1 25
-30.9%
45.8%
Q4 24
8.1%
Q3 24
5.4%
46.3%
Q2 24
-10.7%
49.1%
Net Margin
ORGO
ORGO
SRCE
SRCE
Q1 26
35.3%
Q4 25
19.4%
37.1%
Q3 25
14.3%
38.2%
Q2 25
-9.3%
34.5%
Q1 25
-21.7%
36.1%
Q4 24
6.1%
32.1%
Q3 24
10.7%
35.7%
Q2 24
-13.1%
37.8%
EPS (diluted)
ORGO
ORGO
SRCE
SRCE
Q1 26
$1.63
Q4 25
$0.31
$1.67
Q3 25
$0.11
$1.71
Q2 25
$-0.10
$1.51
Q1 25
$-0.17
$1.52
Q4 24
$0.05
$1.27
Q3 24
$0.09
$1.41
Q2 24
$-0.13
$1.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORGO
ORGO
SRCE
SRCE
Cash + ST InvestmentsLiquidity on hand
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$300.1M
$1.3B
Total Assets
$598.7M
$9.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORGO
ORGO
SRCE
SRCE
Q1 26
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Total Debt
ORGO
ORGO
SRCE
SRCE
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
ORGO
ORGO
SRCE
SRCE
Q1 26
$1.3B
Q4 25
$300.1M
$1.3B
Q3 25
$255.1M
$1.2B
Q2 25
$233.2M
$1.2B
Q1 25
$242.9M
$1.2B
Q4 24
$262.9M
$1.1B
Q3 24
$278.5M
$1.1B
Q2 24
$263.5M
$1.0B
Total Assets
ORGO
ORGO
SRCE
SRCE
Q1 26
$9.1B
Q4 25
$598.7M
$9.1B
Q3 25
$509.8M
$9.1B
Q2 25
$461.1M
$9.1B
Q1 25
$467.4M
$9.0B
Q4 24
$497.9M
$8.9B
Q3 24
$446.3M
$8.8B
Q2 24
$443.2M
$8.9B
Debt / Equity
ORGO
ORGO
SRCE
SRCE
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORGO
ORGO
SRCE
SRCE
Operating Cash FlowLast quarter
$39.4M
$59.1M
Free Cash FlowOCF − Capex
$34.8M
$58.1M
FCF MarginFCF / Revenue
15.4%
51.4%
Capex IntensityCapex / Revenue
2.1%
0.9%
Cash ConversionOCF / Net Profit
0.90×
1.48×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M
$361.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORGO
ORGO
SRCE
SRCE
Q1 26
$59.1M
Q4 25
$39.4M
$223.1M
Q3 25
$3.1M
$51.0M
Q2 25
$-32.9M
$44.9M
Q1 25
$-19.9M
$71.8M
Q4 24
$10.9M
$193.9M
Q3 24
$8.7M
$68.4M
Q2 24
$4.7M
$50.0M
Free Cash Flow
ORGO
ORGO
SRCE
SRCE
Q1 26
$58.1M
Q4 25
$34.8M
$213.0M
Q3 25
$844.0K
$47.3M
Q2 25
$-36.5M
$43.0M
Q1 25
$-23.6M
$69.3M
Q4 24
$7.6M
$181.5M
Q3 24
$6.1M
$66.7M
Q2 24
$2.9M
$46.4M
FCF Margin
ORGO
ORGO
SRCE
SRCE
Q1 26
51.4%
Q4 25
15.4%
192.2%
Q3 25
0.6%
42.7%
Q2 25
-36.1%
39.8%
Q1 25
-27.2%
66.6%
Q4 24
6.0%
185.5%
Q3 24
5.3%
68.1%
Q2 24
2.2%
47.7%
Capex Intensity
ORGO
ORGO
SRCE
SRCE
Q1 26
0.9%
Q4 25
2.1%
9.1%
Q3 25
1.5%
3.4%
Q2 25
3.6%
1.7%
Q1 25
4.2%
2.4%
Q4 24
2.7%
12.6%
Q3 24
2.2%
1.7%
Q2 24
1.4%
3.7%
Cash Conversion
ORGO
ORGO
SRCE
SRCE
Q1 26
1.48×
Q4 25
0.90×
5.42×
Q3 25
0.14×
1.21×
Q2 25
1.20×
Q1 25
1.91×
Q4 24
1.43×
6.17×
Q3 24
0.71×
1.96×
Q2 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons